Emerging Pharmaceutical Organization Awards $1.7 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Informat

Emerging Pharmaceutical Organization Awards $1.7 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information Distribution
Services
Thorough Phase I ECG Study to be Conducted for Cardio-Renal Product 


PHILADELPHIA, June 14  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has
received an agreement for about $1.7 million in cardiac safety monitoring and
services from an emerging pharmaceutical organization for one of its drug
candidates in clinical development.

The agreement covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow-enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.  The study is
targeted for completion over a 90-day period.

"With less than one month from award to trial start, eRT is pleased to be in a
position to meet the demanding timeframes for this significant Thorough Phase I
ECG Study, which is critical to the clinical development program for this
compound," said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT.  "eRT's scientific consulting helped the
drug developer implement an optimal plan for ECG collection and analysis for
this novel therapy in the Cardio-Renal Division of the FDA, and our company's
unmatched capacity and throughput will help to ensure on-schedule study
conduct."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The sponsor may cancel this agreement at its sole discretion.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology,

Inc.



Web site:  http://www.ert.com/ 

Copyright